dc.creatorDuschak, Vilma G
dc.date2019-12-04T18:54:21Z
dc.date2019-12-04T18:54:21Z
dc.date2016
dc.date.accessioned2023-08-29T20:06:22Z
dc.date.available2023-08-29T20:06:22Z
dc.identifier2212-4071
dc.identifierhttp://sgc.anlis.gob.ar/handle/123456789/1428
dc.identifier10.2174/1574891X11666161024165304
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8519116
dc.descriptionFil: Duschak, Vilma G. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.
dc.descriptionThe American trypanosomiasis, Chagas disease, is a parasitic infection typically spread by triatomine vectors affecting millions of people all over Latin America. Existing chemotherapy is centered on the nitroaromatic compounds benznidazole and nifurtimox that provide unsatisfactory results and substantial side effects. So, the finding and exploration of novel ways to challenge this neglected disease is a main priority.
dc.languageen
dc.publisherBentham Science Publishers
dc.relationRecent patents on anti-infective drug discovery
dc.rightsnone
dc.sourceRecent patents on anti-infective drug discovery 2016;11(2):74-173.
dc.subjectTrypanosoma cruzi
dc.subjectEnfermedad de Chagas
dc.subjectPatente
dc.titleTargets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period
dc.typeArtículo


Este ítem pertenece a la siguiente institución